RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial

被引：1
|
作者：
Johnson, M. L. [1 ]
Langdon, R. [2 ]
Ellison, D. [3 ]
Spira, A. [4 ]
Amin, H. [5 ]
Castine, M. [6 ]
Daniel, D. B. [7 ]
Sohoni, S. [8 ]
Chen, Y-C. [8 ]
Hayes, J. [8 ]
Mu, Y. [8 ]
Masciari, S. [9 ]
Wang, X. [8 ]
Toya, S. [10 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[2] Nebraska Canc Specialists, Omaha, NE USA
[3] Charleston Oncol PA, Charleston, SC USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Boca Raton Clin Res Associates Inc, Plantation, FL USA
[6] Hematol Oncol Clin, Baton Rouge, LA USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Chattanooga, TN USA
[8] Revolut Med, Redwood City, CA USA
[9] Sanofi, Cambridge, MA USA
[10] GenHarp Clin Solut LLC, Evergreen Pk, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
76TiP
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial
    Wang, Huaying
    Tian, Wenjuan
    Ren, Yulan
    Lu, Jing
    Wang, Tingting
    Li, Haiming
    Jing, Chuyu
    Shan, Boer
    Yang, Huijuan
    Cheng, Xi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
    Skoulidis, Ferdinandos
    De langen, Adrianus
    Paz-Ares, Luis G.
    Mountzios, Giannis Socrates
    Curioni-Fontecedro, Alessandra
    Couraud, Sebastien
    Janssens, Annelies
    Rocco, Danilo
    Ohashi, Kadoaki
    Vincent, Mark David
    Kang, Jin-Hyoung
    Schvartsman, Gustavo
    Lindsay, Colin R.
    O'Byrne, Kenneth John
    Dziadziuszko, Rafal
    Andersen, Jon A. Lykkegaard
    Hindoyan, Antreas
    Wilmanski, Tomasz
    Wang, Yang
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial
    Tian, Wenjuan
    Ren, Yulan
    Lu, Jing
    Jing, Chuyu
    Zhang, Wei
    Li, Haiming
    Wang, Tingting
    Hou, Zhiguo
    Yang, Ting
    Zhu, Wenqing
    Zhang, Yi
    Shan, Boer
    Yang, Huijuan
    Cheng, Xi
    Wang, Huaying
    BMC MEDICINE, 2024, 22 (01):
  • [34] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9016 - LBA9016
  • [35] A PHASE II OPEN LABEL TRIAL OF PF-00299804 MONOTHERAPY IN PATIENTS WITH HER-2 POSITIVE ADVANCED GASTRIC CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    Lee, K. -H.
    Oh, D. -Y.
    Lee, K. -W.
    Cho, J. Y.
    Kang, W. K.
    Rha, S. Y.
    Bang, Y. -J.
    ANNALS OF ONCOLOGY, 2012, 23 : 19 - 20
  • [36] A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen.
    Oh, Do-Youn
    Lee, Keun-Wook
    Cho, Jae Yong
    Kang, Won Ki
    Rha, Sun Young
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [37] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [39] Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).
    Xu, Jie
    Xie, Lu
    Guo, Wei
    Tang, Xiaodong
    Yang, Rongli
    Yan, Taiqiang
    Liu, Kuisheng
    Gu, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopheri J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345